| Autor: |
Marta Rodríguez, Ruth Alonso‐Alonso, Ismael Fernández‐Miranda, Rufino Mondéjar, Laura Cereceda, Álvaro Tráscasa, Anabel Antonio‐Da Conceiçao, Jennifer Borregón, Lucía Gato, Laura Tomás‐Roca, Carmen Bárcena, Begoña Iglesias, Fina Climent, Eva González‐Barca, Francisca Inmaculada Camacho, Émpar Mayordomo, Gabriel Olmedilla, Pilar Gómez‐Prieto, Yolanda Castro, Juana Serrano‐López, Joaquín Sánchez‐García, Santiago Montes‐Moreno, Mónica García‐Cosío, Paloma Martín‐Acosta, Juan F. García, María Planelles, Cristina Quero, Mariano Provencio, Ignacio Mahíllo‐Fernández, Socorro M. Rodríguez‐Pinilla, Enrico Derenzini, Stefano Pileri, Margarita Sánchez‐Beato, Raúl Córdoba, Miguel A. Piris |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
eJHaem, Vol 3, Iss 3, Pp 722-733 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2688-6146 |
| DOI: |
10.1002/jha2.457 |
| Popis: |
Abstract Diffuse large B‐cell lymphoma (DLBCL), the most frequent non‐Hodgkin's lymphoma subtype, is characterized by strong biological, morphological, and clinical heterogeneity, but patients are treated with immunochemotherapy in a relatively homogeneous way. Here, we have used a customized NanoString platform to analyze a series of 197 homogeneously treated DLBCL cases. The platform includes the most relevant genes or signatures known to be useful for predicting response to R‐CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) in DLBCL cases. We generated a risk score that combines the International Prognostic Index with cell of origin and double expression of MYC/BCL2, and stratified the series into three groups, yielding hazard ratios from 0.15 to 5.49 for overall survival, and from 0.17 to 5.04 for progression‐free survival. Group differences were highly significant (p < 0.0001), and the scoring system was applicable to younger patients ( |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text